MedTrace Logo

A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients

NCT04950803 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 448

Last updated 2024-08-22

No results posted yet for this study

Summary

This study aims to evaluate the effectiveness of an oral microbiome immunity formula in modulating gut microbiota, enhancing immunity and reducing long-term complications and co-morbidities in patients who have recovered from COVID-19.

Conditions

Interventions

DIETARY_SUPPLEMENT

Microbiome immunity formula

Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)

DIETARY_SUPPLEMENT

Active placebo

Active placebo contains active vitamin

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Siew Ng · CUHK-M&T

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-25
Primary Completion
2027-05-31
Completion
2027-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04950803 on ClinicalTrials.gov